

January 30, 2023

Danielle Mayhew  
Legal Counsel, Regulatory Affairs  
Toronto Stock Exchange  
100 Adelaide Street West, Suite 300  
Toronto, Ontario M5H 1S3  
Email: [tsxrequestforcomments@tsx.com](mailto:tsxrequestforcomments@tsx.com)

**Re: Request for Comments**

Dear Ms. Mayhew,

Oncolytics Biotech Inc. fully supports the proposed amendments to Section 606 – Prospectus Offerings of the Toronto Stock Exchange Company Manual (the “Company Manual”) as outlined on December 1, 2022. Most importantly, we feel strongly that pricing decisions for a prospectus offering should be left in the hands of the issuer’s officers and directors. As a Canadian biotech company involved in cancer therapy drug development, we rely on the equity capital markets to fund our operations while we progress toward approval. We compete for capital not only in the Canadian market but in the US market as well. Trying to compete for US investment capital under the current Company Manual, when the US regulatory regime recognizes that the officers and directors are in the best position to make pricing decisions, places Canadian public companies at a significant disadvantage.

Oncolytics believes the proposed amendments would put Canadian biotech issuers on a level playing field with their competitors giving us a better chance for success.

Please feel free to contact me directly if you have any questions or wish to discuss these issues further.

Yours truly,

*Kirk Look*

Kirk Look, CA, MSJ  
CFO